Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients

Figures & data

Figure 1 RFLP for CYP3A5. Lane M, base pair marker (250-bp DNA ladder); lanes 1–3, SspI-digested PCR products from three PCR products. CYP3A5^*3/^*3 genotype gives 168- and 125-bp bands (lane 3) and CYP3A5^*1/^*3 genotype gives 168-, 148-, 125-, and 20-bp (lanes 1 and 2). The 20-bp band is not visible. CYP3A5^*1/^*1 genotype is not seen in this picture. Analysis on a 3.5% agarose/Tris-borate-EDTA gel.

Table 1 Characteristics of patient population

Characteristic
Age (years, mean (SD))	35.08 (16.31)
Gender (male/female)	5/7
Weight (kg, mean (SD))	69.63 (8.46)
Transplantation number (first/second)	10/2
Cadaver transplant donor	12
Age at the onset of the chronic renal deficiency (years, mean (SD))	30.58 (15.53)

Table 2 Tacrolimus pharmacokinetics and hepatic function with and without coadministration of omeprazole

Parameter	With (mean ± SD)	Without (mean ± SD)	P
Concentration (ng/mL)	9.80 ± 3.70	9.32 ± 3.86	0.3409
Daily dose (mg/kg/day)	0.10 ± 0.05	0.11 ± 0.07	0.2335
Concentration/dose ((ng/mL)/(mg/kg))	135.05 ± 93.96	129.16 ± 92.39	0.7203
Volume of distribution (L/kg)	11.12 ± 7.48	13.06 ± 13.25	0.7182
Aspartate aminotransferase (U/L)	17 ± 9	18 ± 7	0.0718
Alanine aminotransferase (U/L)	24 ± 18	22 ± 15	0.9791
γ-Glutamyltransferase (U/L)	27.81 ± 16.79	28 ± 24	0.3447
Bilirubin (mg/dL)	0.50 ± 0.24	0.51 ± 0.23	0.6327